Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IK-01 vs microfracture for focal knee cartilage injury and osteochondritis dissecans (Phase 3)
jRCT1080224103Phase 3Completed
- Sponsor
- Hirosaki Lifescience Innovation, Inc.
- Start
- Oct 2018
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial of CaReS in Cartilage Injury of the Knee and Osteochondritis dissecans of the knee (OCD) (4 arms), sponsored by Hirosaki Lifescience Innovation, Inc. Started Oct 2018; status: completed.
02
Drugs
CaReS
03
Conditions
Cartilage Injury of the KneeOsteochondritis dissecans of the knee (OCD)
Beyond the preview
Go deeper on jRCT1080224103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224103.